Aardvark Therapeutics, Inc. (AARD) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$1.24

From 52W high−92.16%

Volume199219.00

Market cap$27.14M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataNov 4, 2026

Open

$1.24

From 52W high

−92.16%

Volume

199219.00

Market cap

$27.14M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

0.7x

P/E (TTM)

—

RSI (14)

24.1

MomentumView details →

1D Return

+0.81%

YTD Return

−91.09%

SummaryUpdated Jun 1, 2026

Aardvark Therapeutics, Inc. (NASDAQ:AARD) is a clinical-stage biopharmaceutical company founded in 2017 and headquartered in San Diego, California. The company specializes in developing innovative small-molecule therapeutics that target the body's natural homeostatic pathways to treat metabolic diseases. Since its incorporation, Aardvark has focused on addressing rare metabolic disorders through a novel approach of activating bitter taste receptors in the gastrointestinal tract, representing a unique therapeutic strategy in the biotechnology sector.

Ask drillr about Aardvark Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

0.7x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

0.4x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−93.44%

ROA (TTM)

−85.80%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

−53.59%

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

−82.89%

MomentumView details →

1D Return

+0.81%

YTD Return

−91.09%

1Y Return

−88.86%

RSI (14)

24.1

vs 50D SMA

−73.57%

vs 200D SMA

−80.84%

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

12.63x

Quick Ratio

12.63x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.66

EPS Surprise

24.52%

Beats (12Q)

3/12

Next Q EPS Est

−$0.69

Avg Surprise (4Q)

5.34%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−69.89M

Op. CF (TTM)

−69.41M

Next earningsNov 12, 2026 →

Latest newsMore news →

The FDA lifted its clinical hold on Aardvark Therapeutics, Inc.’ Phase 3 HERO trial and open-label extension study of ARD-101, allowing clinical development to resume.12d ago

Aardvark Therapeutics, Inc. shares fell 48.61% to $2.03.12d ago

Similar companies

TransCode Therapeutics, Inc.RNAZ Polyrizon Ltd.PLRZ Evaxion Biotech A/SEVAX NextCure, Inc.NXTC BeyondSpring Inc.BYSI ABVC BioPharma, Inc.ABVC Find similar companies →

Latest newsMore news →

The FDA lifted its clinical hold on Aardvark Therapeutics, Inc.’ Phase 3 HERO trial and open-label extension study of ARD-101, allowing clinical development to resume.12d ago Aardvark Therapeutics, Inc. shares fell 48.61% to $2.03.12d ago A class action lawsuit alleging federal securities law violations was filed against Aardvark Therapeutics, Inc.24d ago